TO Deeply transform global health
strategic industrial partnershipS to lead our proof of concept-validated candidate vaccines into clinical trials and onTO the market
THE BIGGEST REVOLUTION IN VACCINATION SINCE THE RABIES VACCINE
Pasteur Institute collaboration
A JOINT LABORATORY WAS SET UP BETWEEN PASTEUR INSTITUTE AND THERAVECTYS TO ACCELERATE DEVELOPMENT AND TO CAPITALIZE ON THE DISCOVERIES OF THE MOLECULAR VIROLOGY AND VACCINOLOGY UNIT
In 2017, the Pasteur Institute and Theravectys created a Joint Laboratory. In this first-ever and only joint laboratory in the history of the Pasteur Institute, Pierre Charneau works with his research team on lentiviral vectors which could enable a dramatic paradigm shift in the field of vaccinology.
Theracectys relies on its proprietary platform to provide remarkably safe and effective T-cell vaccines in response to critical unmet medical needs.
Theravectys’ pioneering technology and global licensing field enable an almost unlimited number of applications in infectious diseases (such as HIV, malaria, coronavirus, and tuberculosis), viral-induced cancers, solid cancers, and many other diseases.